Atrial Fibrillation (AF)
309
111
137
36
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 309 trials
100.0%
+13.5% vs benchmark
8%
24 trials in Phase 3/4
11%
4 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 36 completed trials
Clinical Trials (309)
Caffeine Consumption and Rate Control in Permanent Atrial FIBrillation: The CAFIB Trial
Medical Large Language Model-Assisted Diagnosis and Treatment in Primary Care Chronic Disease Management
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
Association of Lipoprotein(a) With Postoperative Atrial Fibrillation
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
Remimazolam-Fentanyl Mild Conscious Sedation Regimen in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation
Restoring Sinus Rhythm Using Dual-Shock Technique in Patients With Atrial Fibrillation
FARAPULSE Workflow Assessment Registry
The COMBINE-AF Trial
Comparative Evaluation of the Efficacy and Safety of High-Power Short-Duration Radiofrequency Ablation and Standard Low-Power Ablation in Catheter Treatment of Atrial Fibrillation
Efficacy and Safety of Superior Vena Cava Isolation and Pulmonary Vein Isolation for Treatment of Atrial Fibrillation
Performance After Cardiac Ablation in Endurance Athletes for Atrial Fibrillation
Empirical Anatomy-Based Ablation vs Emphasize Map-Guided Substrate Ablation in Persistent Atrial Fibrillation : (COMPASS-AF)
Clinical Validation of SMD-RVECG for Predicting Atrial Fibrillation With Rapid Ventricular Response Within 2 Hours
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Assessment of Catheter Tissue Contact in PFA
Clinical Validation of SMD-AFECG for Predicting New-Onset Atrial Fibrillation Within 2 Hours Using Single-Lead ECG Data
Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation
PulseMagic™ TrueForce™ PAF NMPA Study